Luye Pharma AG, a German subsidiary of China’s Luye Pharma Group, will supply hospitals and pharmacies in nearly 50 Chinese cities. Rivastigmine is a treatment for mild to moderate Alzheimer’s disease and is administered transdermally once a day. It passes through the epidermis and is absorbed by blood vessels in the dermis to enter the whole body, circulate in the blood, and reach an effective blood concentration. In 2021, there were about 9 million patients in China, and it is estimated that there will be 21 million in 2050.
Japan JST China news, January 25, 2021
Luye Pharma AG supplies rivastigmine transdermal patch for Chinese Alzheimer patients